Stockscreener 앱 받기
105.44
0.69%
0.72
시간 외 거래:
105.44
전일 마감가:
$104.72
열려 있는:
$105.96
하루 거래량:
770.16K
Relative Volume:
0.98
시가총액:
$6.73B
수익:
$46.02M
순이익/손실:
$-130.15M
주가수익비율:
-51.62
EPS:
-2.0427
순현금흐름:
$56.08M
1주 성능:
+3.28%
1개월 성능:
+14.16%
6개월 성능:
+35.74%
1년 성능:
+124.58%
1일 변동 폭
$103.02
$106.66
1주일 범위
$95.40
$106.66
52주 변동 폭
$41.28
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
105.44 | 6.68B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN
Jefferies reiterates Protagonist Therapeutics stock rating on Icotyde outlook By Investing.com - Investing.com Canada
Protagonist Therapeutics Jumps 7.0% in Broad Rally - AlphaStreet
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com South Africa
Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com
Trading Systems Reacting to (PTGX) Volatility - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Maintained Buy: Jefferies and Johnson Rice on Protagonist Therapeutics (PTGX) March 2026 - Meyka
PTGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AI Stocks: Is Protagonist Therapeutics Inc forming a bullish divergence2026 Chart Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Investor Mood: Will Protagonist Therapeutics Inc benefit from rate cuts2026 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Is Protagonist Therapeutics Inc stock good for income investors2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Protagonist Therapeutics Price Target Raised to $116.00/Share From $104.00 by Clear Street - Moomoo
PTGX: Clear Street Raises Price Target for Protagonist Therapeutics | PTGX Stock News - GuruFocus
Clear Street Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $116 - Moomoo
Clear Street raises Protagonist Therapeutics price target on drug potential By Investing.com - Investing.com India
Clear Street raises Protagonist Therapeutics price target on drug potential - Investing.com
SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Protagonist Therapeutics, Inc. (PTGX) stock price, news, quote and history - Yahoo Finance Singapore
Jobs Data: Will Protagonist Therapeutics Inc benefit from AI trends2026 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
This Healthcare Stock Barely Flinches During Market Sell-Offs - The Motley Fool
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026 - Meyka
Protagonist Therapeutics (NASDAQ:PTGX) Surges To New High Amid Nasdaq Today Focus - Kalkine Media
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 105.71 USD By Investing.com - Investing.com India
How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing - Stock Traders Daily
Protagonist Therapeutics stock hits all-time high at 105.71 USD - Investing.com
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following ICOTYDE’s Phase 3 Psoriasis Data ReleaseLearn Why - simplywall.st
Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing - marketscreener.com
Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing - MarketScreener
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Reno Gazette Journal
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting - bitget.com
Protagonist presents one-year data for psoriasis drug ICOTYDE - Investing.com
Protagonist Therapeutics (MEX:PTGX) PE Ratio : At Loss (As of Mar. 28, 2026) - GuruFocus
Arturo Md Molina Sells 15,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):